Antithrombin III treatment for portal vein thrombosis after living donor liver transplantation: a case report
Surgical Case Reports volume 6, Article number: 159 (2020)
There have been no reports on the effectiveness of the administration of antithrombin III (AT III) for post-transplant portal vein thrombosis (PVT). We herein report a case of post-transplant PVT that was resolved by AT III treatment after living donor liver transplantation (LDLT).
The patient was a 57-year-old man who had been diagnosed with decompensate liver cirrhosis by hepatitis C virus infection. He presented with repeated hepatic coma and refractory ascites. Computed tomography (CT) revealed PVT of Yerdel classification grade II before LDLT. He underwent ABO-identical LDLT using a right lobe graft. A liver function test revealed elevated liver enzyme levels on post-operative day (POD) 14. The CT examination on POD 15 revealed PVT in the left side of the main portal vein at the side of left gastric vein ligation. AT III treatment from POD 15 to POD 24 was performed. Magnetic resonance imaging revealed that the PVT had decreased 10% on POD 27. Furthermore, AT III treatment from POD 28 to POD 32 was performed. The CT examination demonstrated the disappearance of PVT on POD 69 and thereafter, he had no recurrence of PVT on 10 post-operative month (POM).
The present case suggests that the administration of AT III is safe and suitable for the treatment of post-transplant PVT.
PVT is a serious and common problem in patients with liver cirrhosis who are candidates for liver transplantation (LT) . PVT can significantly cause a poor recipient prognosis after LT  and can cause a contraindication of re-LT. Hidaka H et al. reported the effect of the administration of AT III for PVT in patients with chronic liver disease , and Imai H et al. reported the effect of the administration of AT III for pre-transplant PVT . However, there have been no reports on the effectiveness of the administration of AT III for post-transplant PVT. We herein report a case of post-transplant PVT that was resolved by AT III treatment after LDLT.
The patient was a 57-year-old man who had been diagnosed with decompensate liver cirrhosis by hepatitis C virus infection. He was treated with asunaprevir and daclatasvir from 2015 and achieved a sustained virological response. Since 2017, he presented with repeated hepatic coma and refractory ascites. His Child-Pugh score was 10 and model for end-stage liver disease score was 15. CT revealed PVT of Yerdel classification grade II before LDLT (Fig. 1a, b). AT III treatment (1500 units per day) for 10 days was performed twice but PVT was progressed (Fig. 1c, d). He underwent ABO-identical LDLT using a right lobe graft of his son. The graft weight was 545 g, and the graft-recipient body weight ratio was 0.81. For the recipient operation, Mercedes-Benz incisions were made. After dissection of the main portal vein (PV), the PVT was promptly removed and total hepatectomy was performed. The graft had five hepatic veins (HVs), including the right hepatic vein (RHV; 20 mm), the inferior RHV (IRHV; 9 mm), two V5 (7 and 10 mm), and V8 (12 mm) branches. The graft V5 and V8 branches were formed into single orifice using the recipient’s PV of the extracted liver and donor’s round ligament of the liver as anterior patch graft. Thereafter, HV reconstruction was performed between the recipient’s RHV and the graft formed HVs. IRHV was not anastomosed. The PV reconstruction was performed between the recipient’s main PV and the graft right PV. Hepatic artery reconstruction was performed between the recipient’s right hepatic artery and the graft right hepatic artery under a microscope. Biliary reconstruction was performed with a choledochocholedochostomy.
Intra-operative and post-operative color Doppler ultrasonography was performed to assess the blood flow velocity and pattern. On POD 3, he was treated with low molecular weight heparin (LMWH) as prophylaxis against post-operative venous thrombosis. On POD 5, anticoagulant therapy was ceased due to abdominal bleeding. The abdominal bleeding improved by conservative treatment. Thereafter, the post-operative course was good; however, a liver function test revealed elevated liver enzyme levels on POD 14. The laboratory findings on POD 14 were as follows: total bilirubin, 2.76 mg/dl; direct bilirubin, 0.49 mg/dl; aspartate amino transferase, 40 U/L; alanine aminotransferase, 122 U/L; prothrombin time, 14.1 s; activated partial thromboplastin time, 37.5 s; AT III activity, 68.7 %; fibrinogen degradation product (FDP), 7.6 μg/ml; D-dimer, 6.3 μg/ml; protein C, 71.9%; platelet 5.0 × 104/μℓ. The periodic CT examination on POD 15 revealed PVT in the left side of the main PV at the side of left gastric vein ligation (Fig. 2a, b). AT III treatment (1500 units per day) from POD 15 to POD 24 was performed. Magnetic resonance imaging revealed that the PVT had decreased 10% on POD 27. Furthermore, AT III treatment (1500 units per day) from POD 28 to POD 32 was performed. Figure 3 showed the chronological changes of AT III, FDP, D-dimer during the period of AT III treatment. During the period of AT III treatment, the AT III activity remained above 100%, and FDP and D-dimer levels decreased. On POD 52, he was discharged from the hospital. The CT examination demonstrated the disappearance of PVT on POD 69 (Fig. 4a, b) and thereafter, he had no recurrence of PVT on 10 POM.
PVT occurs in approximately 3-7% after LT and can be fatal for both the graft and recipient [5,6,7,8]. Factors associated with post-transplant PVT include technical issues, preexisting PVT requiring thromboendovenectomy at the time of LT, small PV size (< 5 mm), earlier splenectomy, and use of venous conduits for PV reconstruction [5,6,7,8]. In this case, he had preexisting PVT requiring thromboendovenectomy at the time of LT and he had risk factor for post-transplant PVT. At present, recipients with post-transplant PVT have been treated with anticoagulation (heparin or LMWH or vitamin K antagonists and so on) [9,10,11]. But there are no standard treatments for post-transplant PVT.
AT III is a coagulation regulator synthesized in the liver. AT III is a physiologic inhibitor of thrombin, factor Xa, and other serine proteases. The administration of AT III suppresses the hypercoagulable state, and PVT disappears due to the secondary action of the fibrinolytic system. Hidaka H et al. reported the effect of the administration of AT III for PVT in patients with chronic liver disease . However, there have been no reports about the usefulness of AT III treatment for post-transplant PVT. The present case was only treated with AT III for PVT, and PVT disappeared. Therefore, PVT was dissolved with AT III alone in the present case. The patient showed no complications after the administration of AT III and was discharged. Hidaka H et al. reported the overall incidences of adverse effects did not differ significantly between the AT III group and the placebo group . The most important advantages of AT III over anticoagulants are expected to include fewer adverse effects and an extremely low likelihood of serious life-threatening complications, especially bleeding . As of 10 POM, he had no signs of recurrence of PVT.
Although the accumulation of experience of similar cases will be necessary to validate these findings, the present case suggests that the administration of AT III is safe and suitable for the treatment of post-transplant PVT.
Availability of data and materials
We confirm that the data supporting the findings of this study are available within the article and its supplementary materials.
- AT III:
Portal vein thrombosis
Living donor liver transplantation
Right hepatic vein
Inferior right hepatic vein
Low molecular weight heparin
Fibrinogen degradation product
Nonami T, Yokoyama I, Iwatsuki S, Starzl TE. The incidence of portal vein thrombosis at liver transplantation. Hepatology. 1992;16:1195–8.
Rana A, Hardy MA, Halazun KJ, Woodlamd DC, Ratner LE, Samstein B, et al. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. Am J Transplant. 2008;8:2537–46.
Hidaka H, Kokubu S, Sato T, Katsushima S, Izumi N, Igura T, et al. NPB-06 study group. Antithrombin III for portal vein thrombosis in patients with liver disease: a randomized, double-blind, controlled trial. Hepatol Res. 2018;48:E107–16.
Imai H, Egawa H, Kajiwara M, Nakajima A, Ogura Y, Hatano E, et al. Resolution of preoperative portal vein thrombosis after administration of antithrombin III in living donor liver transplantation: case report. Transplant Proc. 2009;41:3931–3.
Kishi Y, Sugawara Y, Matsui Y, Akamatsu N, Makuuchi M. Late onset portal vein thrombosis and its risk factors. Hepatogastroenterology. 2008;55:1008–9.
Llado L, Fabregat J, Castellote J, Ramos E, Torras J, Jorba R, et al. Management of portal vein thrombosis in liver transplantation: influence on morbidity and mortality. Clin Transplant. 2007;21:716–21.
Seu P, Shackleton CR, Shaked A, Imagawa DK, Olthoff KM, Rudich SR, et al. Improved results of liver transplantation in patients with portal vein thrombosis. Arch Surg. 1996;131:840–4.
Charco R, Fuster J, Fondevila C, Ferrer J, Mans E, Garcia-Valdecasas JC. Portal vein thrombosis in liver transplantation. Transplant Proc. 2005;37:3904–5.
Delgado MG, Seijo S, Yepes I, Achecar L, Catalina MV, Garcia-Criado A, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol hepatol. 2012;10:776–83.
Villa E, Camma C, Marietta M, Luong M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation on patients with advanced cirrhosis. Gatroenterology. 2012;143:1253–60.
Naeshiro N, Aikata H, Hyogo H, Kan H, Fujino H, Kobayashi T, et al. Efficacy and safety of anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. Hepatol Res. 2015;45:656–62.
I would like to give heartful thanks to Prof. Naohiro Sata whose enormous support and insightful comments were invaluable in my study.
Ethical approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
We declare that we have no funding.
Consent for publication
Consent for publication was obtained from all individual participants included in the study.
We declare that we have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hirata, Y., Sanada, Y., Omameuda, T. et al. Antithrombin III treatment for portal vein thrombosis after living donor liver transplantation: a case report. surg case rep 6, 159 (2020). https://doi.org/10.1186/s40792-020-00920-y
- Antithrombin III
- Portal vein thrombosis
- Living donor liver transplantation
- Liver transplantation